Mr. Schliebner is a clinical strategist with a 25-year background in drug development focused on rare diseases, orphan drugs, and advanced therapeutics. He develops innovative solutions and strategic considerations to help overcome the operational, logistical, and ethical challenges inherent to conducting research in challenging patient populationss. Mr. Schliebner’s efforts are focused on patient-centered approaches to drug development; reducing the burden of clinical trial participation; and leveraging novel and disruptive technologies to bring new therapies to patients faster. Committed to collaborative efforts to further drug development, Mr. Schliebner also serves as the Co-Chair of Global Genes’ Corporate Alliance, he serves on the Board of Uplifting Athletes, and developed active partnerships with other patient-focused organizations, patient advocacy groups, drug development institutes, and academic research centers. He holds a Master’s Degree in Public Health (MPH) from the University of Utah School of Medicine, and completed a Graduate Research Fellowship at The National Institutes of Health.